• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis.

作者信息

Sermet-Gaudelus I, Benaboud Sihem, Bui Stéphanie, Bihouée Tiphaine, Gautier Sophie

机构信息

INSERM U1151, Université Paris Cité, Paris, France; Centre de Référence Maladies Rares Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants malades, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris 75015, France; INSERM U1151, Institut Necker Enfants Malades, Paris, France; European Rare Disease Network-Lung, Frankfurt, Germany.

Service de Pharmacologie Clinique, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France; Unité de Recherche Clinique Necker Cochin, Assistance Publique Hôpitaux de Paris, Paris, France.

出版信息

Lancet. 2024 Jul 13;404(10448):117-120. doi: 10.1016/S0140-6736(24)01134-6. Epub 2024 Jun 28.

DOI:10.1016/S0140-6736(24)01134-6
PMID:38950554
Abstract
摘要

相似文献

1
Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis.患有囊性纤维化的学龄前儿童开始使用依列卡福-特扎卡福-依伐卡福后出现的行为和睡眠问题。
Lancet. 2024 Jul 13;404(10448):117-120. doi: 10.1016/S0140-6736(24)01134-6. Epub 2024 Jun 28.
2
Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes.囊性纤维化-门控和-残留功能基因型的三联疗法。
N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665.
3
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究（SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103）：两项随机、活性对照3期试验的结果
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
4
Mood Swings and Irritability in a Patient With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Case Report.接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗的囊性纤维化患者出现情绪波动和易怒：一例报告
J Clin Psychopharmacol. 2024;44(5):528-530. doi: 10.1097/JCP.0000000000001906. Epub 2024 Aug 22.
5
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.与在囊性纤维化患者中使用依列卡福/替扎卡福/依伐卡福相关的肌酸磷酸激酶升高和横纹肌溶解。
Pediatr Pulmonol. 2024 Jun;59(6):1795-1797. doi: 10.1002/ppul.26980. Epub 2024 Mar 22.
6
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.适合调节剂药物的患者：来自土耳其囊性纤维化登记处的数据。
Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.
7
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
8
Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.淋巴细胞转化试验确诊迟发型超敏反应中成功脱敏至依伐卡托和依列卡托/替扎卡托/依伐卡托的方案
J Investig Allergol Clin Immunol. 2024 Jun 17;34(3):211-213. doi: 10.18176/jiaci.0961. Epub 2023 Nov 15.
9
Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?针对既往患有CFSPID的囊性纤维化儿童的依列卡福/替扎卡福/依伐卡托疗法：这是否属于过度医疗？
J Cyst Fibros. 2024 Mar;23(2):366-367. doi: 10.1016/j.jcf.2023.10.008. Epub 2023 Oct 13.
10
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.依列卡福妥/替扎卡福妥/依伐卡托与囊性纤维化儿童及青少年的炎症：一项回顾性双中心队列研究
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251314706. doi: 10.1177/17534666251314706.

引用本文的文献

1
Cystic Fibrosis Year in Review 2024.2024年囊性纤维化年度回顾
Pediatr Pulmonol. 2025 Aug;60(8):e71222. doi: 10.1002/ppul.71222.
2
Impacts and New Challenges with Highly Effective Modulator Therapies in Younger Children with Cystic Fibrosis.高效调节剂疗法对囊性纤维化幼儿的影响及新挑战
J Clin Med. 2025 Jun 30;14(13):4625. doi: 10.3390/jcm14134625.
3
20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insights.蒙特利尔囊性纤维化相关糖尿病筛查队列20年：关键见解
Eur Respir Rev. 2025 May 14;34(176). doi: 10.1183/16000617.0220-2024. Print 2025 Apr.
4
Recent developments in cystic fibrosis drug discovery: where are we today?囊性纤维化药物研发的最新进展：我们如今处于什么阶段？
Expert Opin Drug Discov. 2025 May;20(5):659-682. doi: 10.1080/17460441.2025.2490250. Epub 2025 Apr 13.
5
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.囊性纤维化：除依列卡福妥/替扎卡福妥/依伐卡福妥之外的新挑战与前景
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323194. doi: 10.1177/17534666251323194. Epub 2025 Mar 31.